This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

Cell & Gene Therapy Summit At ChinaBio Partnering Forum
Shanghai, China
Kerry Hotel Pudong, Shanghai, ChinaApril 28–29, 2026

Dan Liu
Managing Partner at Pivotal bioVenture Partners China
Speaker

Profile

Dr. Dan LIU is currently the Managing Partner of Pivotal BioVenture Partners, in charge of Life Sciences Investment in China. He was the Senior Partner and Managing Partner / Investment Committee Member of several fund at CDH Investments, and responsible for the investment in Healthcare sector, including GemPharmatech (688046.SH), HitGen (688222.SH), I-Mab (IMAB.O), Maixin Biotech & Beijing Strong Biotechnologies (300406) , BrainCo and other successful deals.

Before joining CDH Investments, Dr. LIU worked at Bain & Company in health and consumer sectors consulting businesses. He has served and led strategic projects for several large multinational pharmaceutical and device companies at that time.

Dr. LIU has nearly 20 years of experience in health industry in many fields, including research, business, management, consulting and investment.

Dr. LIU is a well-known investor in China's healthcare and wellness industry. He also serves as a member and senior expert in several industry associations and a review expert of many provincial and municipal technology and talent programs. He was awarded as “TOP 50 Outstanding Investors in China”, “40 Investors Under 40 Years Old” and “Top 10 Investors in Health Sector” by many credible Investment Community and Entrepreneurship Zone.

Agenda Sessions

  • Investor Panel Discussion: Investments in Cell and Gene Therapies and Enabling Technologies

    09:45